| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| OX2-M82F3 | Mouse | Biotinylated Mouse CD200 / OX-2 Protein, Fc,Avitag™ (MALS verified) |  |
|
|
| OX2-H82F7 | Human | Biotinylated Human CD200 / OX-2 Protein, Fc (L234A, L235A, P329G),Avitag™ |  |
|
|
| OX2-H82F1 | Human | Biotinylated Human CD200 / OX-2 Protein, Fc,Avitag™ |  |
|
|
| OX2-H5228 | Human | Human CD200 / OX-2 Protein, His Tag |  |
|
|
| OX2-H5251 | Human | Human CD200 / OX-2 Protein, Fc Tag |  |
|
|
Immobilized Human CD200 R1, His Tag (Cat. No. CR2-H52H6) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD200, Fc (L234A, L235A, P329G),Avitag (Cat. No. OX2-H82F7) with a linear range of 0.2-1 ng/mL (QC tested).
The purity of Biotinylated Mouse CD200, Fc,Avitag (Cat. No. OX2-M82F3) is more than 90% and the molecular weight of this protein is around 125-135 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Samalizumab | ALXN-6000 | Phase 2 Clinical | Alexion Pharmaceuticals Inc, The Leukemia & Lymphoma Society | Solid tumours; Multiple Myeloma; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| CD-200-AR-L | CD-200-AR-L; hP-1-A-8 | Phase 1 Clinical | University Of Minnesota | Glioblastoma | Details |
This web search service is supported by Google Inc.
A-Z
